Teva Launches Generic ADENOSCAN in United States

Teva Pharmaceutical Industries Ltd.

today announced the launch of the generic equivalent to ADENOSCAN® (adenosine injection) in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. ADENOSCAN® is supplied as 20 mL and 30 mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Marketed by Astellas Pharma, ADENOSCAN® had annual sales of approximately $65 million in the United States, according to IMS data as of June 30, 2013.